Exelixis
EXEL
$52.20
-7.94%
Exelixis Inc is a biopharmaceutical company focused on discovering, developing, and commercializing cancer treatments, with its lead molecule cabozantinib marketed as Cometriq for medullary thyroid cancer and Cabometyx for kidney and liver cancer, alongside Cotellic for melanoma developed with Roche. The company holds a strong position in the oncology space, leveraging its expertise in targeted therapies to build a diversified portfolio. Currently, investor attention is centered on the company's robust revenue growth, driven by strong sales of Cabometyx, and its expanding pipeline, which includes potential label expansions and new indications. The stock has seen significant appreciation over the past year, reflecting optimism about its growth trajectory, though recent clinical setbacks in the broader sector and mixed analyst actions introduce some uncertainty.…
EXEL
Exelixis
$52.20
Related headlines
Investment Opinion: Should I buy EXEL Today?
Based on the analysis, Exelixis is rated a Buy. The company's strong revenue growth, high profitability, and attractive valuation on a PEG basis support this rating. The consensus analyst rating is 'Buy' with an average target of $52.07, which is close to the current price, but the high target of $64 implies significant upside. Key supporting data points include a forward PE of 13.1x, a PEG ratio of 0.25, a gross margin of 96.4%, and a net margin of 33.7%. These metrics indicate that the stock is undervalued relative to its growth prospects. However, the rating could be downgraded to Hold if revenue growth decelerates below 8% or if the stock price rises above the average target without corresponding earnings upgrades. Conversely, an upgrade would be warranted if the stock pulls back to below $45, offering a more attractive entry point. Overall, Exelixis is fairly valued to slightly undervalued relative to its history and peers.
Sign up to view all
EXEL 12-Month Price Forecast
The AI assessment is bullish on Exelixis, driven by its solid growth metrics and attractive valuation. The company's revenue growth is accelerating, and its profitability is exceptional. The low PEG ratio suggests the market is not fully pricing in the growth potential. However, the medium confidence reflects the uncertainty around clinical and regulatory outcomes. If the company continues to execute on its pipeline and maintains growth, the stock could re-rate higher. Conversely, any negative clinical data or competitive threat could quickly change the stance to neutral or bearish.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Exelixis's 12-month outlook, with a consensus price target around $52.81 and implied upside of +1.2% versus the current price.
Average Target
$52.81
0 analysts
Implied Upside
+1.2%
vs. current price
Analyst Count
—
covering this stock
Price Range
$41 - $66
Analyst target range
The target price range spans from a low of $41.00 to a high of $64.00, reflecting a wide spread of $23.00, which indicates significant uncertainty about the company's future prospects. The high target of $64.00 assumes continued strong growth in Cabometyx sales and successful pipeline developments, potentially leading to multiple expansion. The low target of $41.00 likely prices in risks such as increased competition, regulatory hurdles, or slower-than-expected adoption of new indications. The wide range suggests that analysts have divergent views on the company's growth trajectory, with the recent downgrade by Truist Securities highlighting some concerns. Overall, the consensus leans bullish, but the modest average target relative to the current price suggests limited upside potential in the near term.
Bulls vs Bears: EXEL Investment Factors
Exelixis presents a compelling bull case with strong revenue growth, high profitability, and an attractive PEG ratio, but the bear case highlights limited upside to analyst targets, high valuation multiples, and concentration risk. Currently, the bull case has stronger evidence due to the company's solid fundamentals and undervaluation on a growth-adjusted basis. The most important tension is whether the market will reward the company's growth with multiple expansion or if the stock remains range-bound due to perceived risks. The resolution of this tension will determine the stock's trajectory over the next 12 months.
Bullish
- Strong Revenue Growth: Q1 2026 revenue grew 9.97% YoY to $610.8M, with sequential growth from $555.4M in Q1 2025. This accelerating trend is driven by robust Cabometyx sales and pipeline expansion.
- Undervalued on PEG Ratio: PEG ratio of 0.25 is well below 1, indicating the stock is undervalued relative to its growth rate. Forward PE of 13.1x is attractive for a company with expected EPS growth of ~15%.
- High Profitability: Gross margin of 96.4% and operating margin of 37.6% demonstrate strong pricing power and operational efficiency. Net margin of 33.7% is exceptional for a biotech.
- Low Debt and Strong Balance Sheet: Debt-to-equity ratio of 0.08 and current ratio of 3.56 indicate a solid financial position. This provides flexibility for R&D investments and potential acquisitions.
Bearish
- Limited Upside to Average Target: Average analyst target of $52.07 is below the current price of $53.03, suggesting the stock may be fairly valued or slightly overvalued. This limits near-term upside potential.
- High Valuation Multiples: PS ratio of 5.1 and PB ratio of 5.48 are elevated, indicating the market is pricing in high growth expectations. Any disappointment could lead to multiple compression.
- Dependence on Cabometyx: Revenue is heavily concentrated in Cabometyx, which is the primary growth driver. Loss of patent protection or increased competition could significantly impact revenue.
- Clinical and Regulatory Risks: Biotech sector faces inherent risks from clinical trial failures and regulatory setbacks. Recent news of Merck's cancer drug setback highlights sector-wide risks that could affect investor sentiment.
EXEL Technical Analysis
Exelixis has been in a sustained uptrend over the past year, with the stock price increasing by 46.41% over the last 12 months. Currently trading at $53.03, the stock is near the upper end of its 52-week range, sitting at approximately 92% of the range (with a low of $33.76 and high of $57.57). This positioning near the highs suggests strong momentum and investor confidence, though it also raises the risk of overextension, especially after a recent pullback from the peak.
Beta
0.42
0.42x market volatility
Max Drawdown
-25.2%
Largest decline past year
52-Week Range
$34-$58
Price range past year
Annual Return
+38.4%
Cumulative gain past year
| Period | EXEL Return | S&P 500 |
|---|---|---|
| 1m | -8.5% | +2.8% |
| 3m | +8.4% | +4.2% |
| 6m | +18.9% | +11.3% |
| 1y | +38.4% | +21.5% |
| ytd | +19.8% | +12.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
EXEL Fundamental Analysis
Exelixis has demonstrated solid revenue growth, with the most recent quarter (Q1 2026) reporting revenue of $610.8 million, a 9.97% year-over-year increase. This growth is driven primarily by product sales, which accounted for $555.0 million of total revenue, while collaboration and license revenues contributed $55.8 million and $56.9 million, respectively. The multi-quarter trend shows accelerating growth, as revenue has risen from $555.4 million in Q1 2025 to $610.8 million in Q1 2026, with sequential increases in each quarter. The company's growth is underpinned by strong demand for Cabometyx, and the expansion of its pipeline suggests this momentum could continue.
Quarterly Revenue
$610812000.0B
2026-04
Revenue YoY Growth
+10.0%
YoY Comparison
Gross Margin
96.7%
Latest Quarter
Free Cash Flow
$916414000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is EXEL Overvalued?
Given that Exelixis is profitable, the primary valuation metric selected is the price-to-earnings (PE) ratio. The trailing PE is 15.13x, while the forward PE is 13.10x, indicating that the market expects earnings growth of approximately 15% over the next year. The gap between trailing and forward PE suggests a positive growth outlook, with the forward multiple implying that earnings are expected to increase. This is supported by a PEG ratio of 0.25, which suggests the stock is undervalued relative to its growth rate, as a PEG below 1 typically indicates undervaluation.
PE
15.1x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 7x~40x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
12.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financially, Exelixis is in a strong position with a debt-to-equity ratio of 0.08 and a current ratio of 3.56, indicating low leverage and ample liquidity. However, the company's revenue is heavily concentrated in Cabometyx, which accounted for the majority of product sales. Any disruption to this franchise, such as patent expiry or competitive pressure, could significantly impact earnings. The company's operating margin of 37.6% is high, but it relies on continued cost discipline and R&D efficiency to maintain profitability. The payout ratio is 0%, so investors rely on capital appreciation, which is sensitive to growth expectations.
FAQ
The key risks for Exelixis include: 1) Concentration risk, as revenue is heavily dependent on Cabometyx; 2) Clinical and regulatory risks, as any trial failure or approval delay could impact growth; 3) Competitive pressure from other oncology drugs; 4) Valuation risk, as the stock trades at a premium to peers on a PS basis. The short ratio of 10.75 indicates significant bearish sentiment, which could amplify downside moves. These risks are ranked by severity, with clinical setbacks being the most severe.
The 12-month forecast for Exelixis is based on three scenarios: Bull case (30% probability) targets $60-$64, driven by strong pipeline progress and multiple expansion; Base case (50% probability) targets $50-$55, assuming steady growth and stable sentiment; Bear case (20% probability) targets $41-$45, if clinical setbacks or competition emerge. The most likely scenario is the base case, with the stock trading around the average analyst target of $52.07. Key assumptions include continued revenue growth of 8-10% and no major negative catalysts.
Exelixis is undervalued on a growth-adjusted basis, as indicated by a PEG ratio of 0.25, which is well below the typical threshold of 1. The forward PE of 13.1x is attractive relative to the expected earnings growth of ~15%. However, on a price-to-sales basis, the stock trades at 5.1x, which is above the sector median, suggesting the market is paying a premium for its growth. Overall, the stock is fairly valued to slightly undervalued relative to its growth prospects, but investors should monitor whether the market continues to reward the company with multiple expansion.
Exelixis is a good buy for investors with a medium-term horizon, given its strong revenue growth of 9.97% YoY and high profitability. The stock trades at a forward PE of 13.1x, which is reasonable for a company with expected EPS growth of ~15%. The PEG ratio of 0.25 suggests undervaluation. However, the average analyst target of $52.07 is close to the current price, limiting near-term upside. The main risk is clinical or regulatory setbacks, which could lead to a decline toward the low target of $41. For investors willing to accept this risk, the stock offers a favorable risk/reward.
Exelixis is suitable for medium-to-long-term investment, given its growth stage and pipeline potential. The stock has a beta of 0.424, indicating lower volatility than the market, which makes it suitable for risk-averse investors. The company does not pay a dividend, so returns are driven by capital appreciation. With a 12-month price appreciation of 46.4%, the stock has shown strong momentum, but short-term trading could be volatile due to clinical data releases. A minimum holding period of 12-18 months is recommended to capture the potential upside from pipeline catalysts.